Envoy Medical

COCH

Market cap $24.6M

Event to Take Place December 11th at 4:30 P.M. ET White Bear Lake, Minnesota--(Newsfile Corp. - December 4, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it will host a fireside chat on Thursday, December 11, 2025, at 4:30 P.M.

Envoy Medical, Inc. (COCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

New Patent Adds to Company's Growing Portfolio of Intellectual Property Focused on Fully Implanted Hearing Devices White Bear Lake, Minnesota--(Newsfile Corp. - December 2, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received its 40th active U.S. Patent from the United States Patent and Trademark Office. The new patent further strengthens the Company's intellectual property portfolio, which includes an additional 45 issued foreign patents.

Patent adds to Envoy Medical's expanding intellectual property portfolio, reinforcing the Company's leadership in next generation cochlear implant innovation White Bear Lake, Minnesota--(Newsfile Corp. - November 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of U.S. Patent No. 12,465,754, granted by the United States Patent and Trademark Office (USPTO) on November 11, 2025.

Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.37 per share a year ago.

Transformational quarter puts Envoy Medical in significantly better position as it eliminated $32 million of debt, strengthened its balance sheet, and further expanded its patent portfolio; In addition, subsequent to quarter end, the Company received FDA approval to expand its pivotal clinical trial to the final stage, restarted enrollment, and successfully raised additional capital White Bear Lake, Minnesota--(Newsfile Corp. - November 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced its corporate and financial results for the third quarter ended September 30, 2025, as well as other subsequent events. Corporate Highlights for Third Quarter 2025: Extinguished over $32 Million in Debt, Strengthening Balance Sheet Advanced Commercialization Planning as FDA Clinical Trial Remains On Track Expanded Patent Portfolio by Securing Additional European Patent Secured Four New Global Patents Successfully Reached Three-Month Follow-Up Milestone in Clinical Trial Secured an Additional Three New Patents Further Expanded Patent Portfolio with New Issuances in the United States Subsequent to Third Quarter 2025 End Received FDA Approval to Expand Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data Announced Closing of Up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Marked three-year anniversary of first successful implantation of fully implanted cochlear implant Announced first three patients were enrolled in the final stage of pivotal clinical trial of the fully implanted investigational Acclaim® cochlear implant "The third quarter was transformational for Envoy Medical as we continue to position ourselves to capitalize on the opportunity ahead of us," said Brent Lucas, Chief Executive Officer of Envoy Medical, "We extinguished $32 million in debt without the issuance of new equity, substantially improving our balance sheet and eliminating the need to satisfy or service that debt in the future.

Envoy Medical, Inc. (COCH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rapid patient enrollment underscores strong market interest and reinforces commercialization opportunity for fully implanted cochlear implants White Bear Lake, Minnesota--(Newsfile Corp. - November 4, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the first three patients have been enrolled in the final stage of the Company's pivotal clinical trial of the full implanted Acclaim® cochlear implant. These initial surgeries in this final stage were performed by Dr. Abraham Jacob at the Center for Neurosciences Ear and Hearing Center in Tucson, Arizona and Dr. Jack Shohet at Shohet Ear Associates in Seal Beach, California, two of the seven investigational sites in the United States.

The Company looks to build on its recent momentum - receiving FDA approval to expand its pivotal clinical trial into the second and final stage White Bear Lake, Minnesota--(Newsfile Corp. - October 29, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the three-year anniversary of the first patient receiving its breakthrough first fully implanted cochlear implant. On October 24, 2022, Craig Eggert became the first patient in the world to be implanted with Envoy Medical's new investigational fully implanted cochlear implant.

White Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the Nasdaq Hearings Panel (the "Panel) has granted the Company's request for continued listing on the Nasdaq Stock Market. In granting the extension, the Panel considered several key developments, including Envoy Medical's recent equity capital raises and debt extinguishment, which combined together substantially increased the Company's stockholders' equity, and the FDA's recent approval of the Company's advancement to the final stage of the fully implanted Acclaim® cochlear implant clinical trial.